Abstract:Studies from recent years have identified a diverse population of both bacteria and fungi in the human vagina and several community signatures have emerged that are associated with susceptibility to infectious disease. A healthy vaginal bacterial microbiome is most frequently dominated by Lactobacillus species [1], yet a combination of other genera are isolated in vaginal swabs in both healthy and diseased states. The vaginal fungal mycobiome is dominated by Ascomycota, of which Candida species are the most abundant. Approximately 20% to 30% of healthy human vaginal samples contain detectable Candida at a single time point, with nearly all of those being C . albicans , and 70% of the population is expected to be vaginally colonized with Candida longitudinally [2]. Despite its prevalence in the healthy vaginal mycobiome, C . albicans is the most common causative agent of vulvovaginal candidiasis (VVC), a cause of significant morbidity in the human population. The next most common species implicated in VVC is C . glabrata , while other species including C . lusitaniae , C . tropicalis , C . parapsilosis , and C . krusei are also known to contribute to vaginal infections [3–5]. Non- albicans Candida species are typically more resistant to antifungal drugs than C . albicans [6], complicating therapeutic options and increasing treatment timelines. A disease state is often distinguished by an exaggerated inflammatory response at the vaginal mucosa [3] that leads to vulvar pruritis and erythema [7]. Polymorphic Candida species can initiate the process of filamentation, morphogenesis from single-celled yeast to multicellular hyphae, which is typically accompanied by increased tissue damage and inflammation [8]. Microbial dysbiosis has long been associated with VVC due to the observation that antibiotic usage dramatically increases the risk of onset. This notion has been challenged by several population studies [9,10]; however, other studies have found a close association between Candida and specific bacteria as well as distinct Lactobacillus species that were associated with decreased observation of fungi in samples or symptomatic VVC [11–15]. Taken together, the evidence suggests that specific bacterial species can have complex impacts on fungal burden and symptomatic infection. Shifts in the vaginal microbiome are also associated with other genital tract infections [13,16] including bacterial vaginosis (BV) and aerobic vaginitis (AV), which are characterized by the displacement of Lactobacillus species by other bacteria such as Gardnerella vaginalis , Streptococcus agalactiae , Staphylococcus aureus , Escherichia coli , and Enterococcus faecalis [17]. Both BV and AV are polymicrobial in nature and are associated with concurrent Candida carriage in many cases [18,19]. Mixed vaginitis, which can include BV or AV together with VVC, is particularly difficult to treat, and during late stages of pregnancy can lead to severe adverse maternal and neonatal outcomes [17,20]. Because it is the most abundant fungal genus in the vagina, this review will focus on the interactions between Candida species and the healthy and pathogenic bacteria found in the vaginal environment. These interactions play a significant role in maintaining homeostasis as well as impacting disease pathogenesis in the genital tract (Fig 1).

Highlight signatures of vaginal microbiota and metabolome contributed to the occurrence and recurrence of vulvovaginal candidiasis

Vaginal Homeostasis Features of Vulvovaginal Candidiasis Through Vaginal Metabolic Profiling

[Longitudinal Analysis of Vaginal Microbiota in Women with Recurrent Vulvovaginal Candidiasis].

Interpretation of vaginal metagenomic characteristics in different types of vaginitis

Candida causes recurrent vulvovaginal candidiasis by forming morphologically disparate biofilms on the human vaginal epithelium

Species composition and dynamic changes of vaginal microbiota in patients with recurrent vulvovaginal candidiasis

Inflammatory invasion on human vaginal mucosa correlated with combined drug treatment and recurrence in recurrent vulvovaginal candidiasis

Clotrimazole-induced shifts in vaginal bacteriome and lipid metabolism: insights into recovery mechanisms in vulvovaginal candidiasis

Diverse Vaginal Microbiomes in Reproductive-Age Women with Vulvovaginal Candidiasis.

Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis

Molecular Analysis of the Diversity of Vaginal Microbiota Associated with Bacterial Vaginosis

Analysis of the structure of vaginal microbiota in vulvovaginal candidiasis

Correlation Analysis of Vaginal Microbiome Changes and Bacterial Vaginosis Plus Vulvovaginal Candidiasis Mixed Vaginitis Prognosis

Association Analysis on Recurrence of Bacterial Vaginosis Revealed Microbes and Clinical Variables Important for Treatment Outcome.

Impact of interkingdom microbial interactions in the vaginal tract

Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance

Landscape of In Situ Cytokine Expression, Soluble C-type Lectin Receptors, and Vitamin D in Patients with Recurrent Vulvovaginal Candidiasis

Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review

Vaginal Microbiota: Potential Targets for Vulvovaginal Candidiasis Infection.

Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis

The Interplay between Candida albicans, Vaginal Mucosa, Host Immunity and Resident Microbiota in Health and Disease: An Overview and Future Perspectives